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58 H. Cao et al.IntroductionOsteonecrosis of the femoral head (ONFH) is a chronic
disease that shows a complicated pathogenesis [1].
Spontaneous repair of ONFH is a slow, discontinuous, and
time-dependent process that might only occur in small
size lesions without concomitant joint fluid seepage [2,3].
Naw et al’s [4] clinical report revealed that 94% of
asymptomatic ONFH will develop to symptomatic ONFH
within 5 years. Untreated ONFH is believed to carry a poor
outcome and often leads to the occurrence of subchondral
collapse within a short period [4,5]. Various surgical pro-
cedures are helpful to relieve pain and improve function
of the affected femoral head in the early stages, however,
the secondary trauma caused by surgical intervention re-
mains an inevitable clinical problem and surgical pro-
cedures may not prevent deformity and collapse in
deteriorating ONFH [6]. Therefore, how to reverse the
early stage of ONFH and promote reparative bone
remodelling becomes the key for maintaining the undes-
troyed joint adjacent to lesion areas and making available
therapies to facilitate a good prognosis. Currently, the
attention of surgeons and researchers is focused on: (1)
enhancing the sensibility and accuracy of diagnosis to
raise the rate of early diagnosis; (2) improving surgical
operation technology or developing minimally invasive
surgery to avoid the secondary trauma caused by surgical
intervention; and (3) exploring drug or grafting products
to promote reparative bone remodelling and obtain a good
prognosis. This article presents a review of ONFH classi-
fication systems, current treatment options, potential
therapies, and the relevant translation barriers in the
context of clinical application and preclinical exploration.
By addressing the relationship between ONFH pathological
characteristics and various treatment options, as well as
stating potential therapies and its translational barriers,
we aim to provide guidance for preferable treatment
options and translation into novel therapies.
ONFH classification systems
Patients with suspected ONFH would have one or more of
the following criteria: (1) throbbing, deep groin pain, and
one or more associated risk factors; and (2) a previous ONFH
in another joint [7]. The suspected ONFH needs further
validation using image detection before distinguishing lesion
progression and choosing treatment options (Figure 1).
ONFH classification systems are excellent tools based on
imaging data that are widely used to stratify the severity
and prognosis, and guide the treatment strategy [8]. There
are several staging systems used for classifying ONFH,
including Ficat and Arlet classification; the University of
Pennsylvania (Steinberg) staging system, Association
Research Circulation Osseous (ARCO), and the Japanese
Orthopaedic Association (JOA) classification systems (Table
1). There are some denominators among them; the diag-
nostic data enable easy conversion to any of the four sys-
tems so that cross-comparison of results can be made [9].
The Ficat and Arlet system was the first classification
system for ONFH and this system includes four stages
[10,11]. Stage I is a transitional stage and patients areasymptomatic with a normal radiographic finding, but with
increased uptake of tracer on bone scintigraphy [10]. Stage
II represents the reparative stage and some diffuse sclerotic
and cystic lesions can be observed before flattening of the
femoral head occurs. Stage III is characterized by sub-
chondral fracture (crescent sign). Stage IV involves the loss
of the femoral head’s anatomical sphericity and the
occurrence of femoral head collapse and joint destruction.
This damage leads to further progressive degeneration such
as osteoarthritis and acetabular degeneration. There are
some drawbacks in this system. Firstly, the descriptions of
various stages are ambiguous and overlapping, and do not
allow quantitation of the size of lesions, which makes it
impossible to measure subtle degrees of progression. Next,
the classification of later stages depends on invasive diag-
nosis techniques, such as core decompression, which would
lead to secondary trauma.
The Steinberg system was established based on the Ficat
and Arlet system, and the important modifications included
the incorporation of magnetic resonance imaging findings
and more clear distinction into seven stages [12]. This
system is the first to incorporate the size of lesion mea-
surements as part of a complete system [13]. The ARCO
system originates from the Steinberg classification, and
several amendments have been made over the years
[14,15]. This system does not provide a method to evaluate
either preradiographic lesions or lesions in which the joint
line and the acetabulum are involved [14]. The location of
ON lesion is detected and the relative information is added
to each stage in ARCO system as a supplement, but its
specific value is uncertain [16,17]. The JOA system origi-
nated from the Ficat and Arlet system with the location and
size of the lesion added to its classification, however, this
system only evaluates Ficat Stages II and III and not Stages I
and IV [18,19].
The goals in treatment of ONFH are to relieve pain and
preserve the femoral head as long as possible. We believe
that an optimal treatment option should be based on an
appropriate classification system of ONFH [7]. Currently,
for treating ONFH, there is a lack of consensus regarding
diagnostic methods, evaluation systems, and indications of
various treatment options [8]. Thus, symptoms, imaging
and histological data, size and location of lesion, and the
indications of articular cartilage involvement and femoral
head depression, should be incorporated together to find a
preferable treatment option for ONFH.
Current treatment options for ONFH
Nonoperative treatments
Most nonoperative treatment for early stage ONFH in-
volves restricted weight bearing using a cane and activity
modification. These methods only work in the early stage,
asymptomatic ONFH, but show limited success in pre-
venting disease progression (Table 2) [5,20]. Restricted
weight bearing cannot be recommended as a routine
treatment, however, such therapies may have a role for
patients with very limited disease or those not fit for
further surgery [21,22]. Other conservative treatments,
including the use of pharmacological agents (such as lipid-
Treatment of osteonecrosis of the femoral head 59lowering drugs, anticoagulants, vasodilators, traditional
Chinese medicines, and bisphosphonates) and various
noninvasive biophysical modalities (such as electromag-
netic stimulation, extracorporeal shock-wave therapy,
and hyperbaric oxygen) are advised for supplemental
treatment of this disease [7,23e32]. The role of drugs for
prevention or treatment is confined to specific aetiological
pathways. In the right circumstances, the medical man-
agement would be able to arrest ONFH development and
induce healing prior to collapse [33]. Meanwhile, these
physical therapies are used to address specific physiolog-
ical factors of ONFH and cannot be recommended as a
routine treatment. Clinical studies have further demon-
strated that conservative therapies do not achieve satis-
factory clinical benefits and are not appropriate for ONFH
with subchondral collapse [34].Operative treatments
Core decompression and bone grafting
Core decompression is the leading surgical treatment for
precollapse ONFH and Mont et al’s [34] clinical research
report showed this operation’s success rate reached 70% on
follow up of  5 years without the need for additional
surgery. Core decompression involves drilling a single 8e10-
mm core into the necrotic lesion that could provide pain
relief and reduce intraosseous pressure [35]. Meanwhile,
this procedure enhances the process of new bone creeping
substitution of the necrotic area by stimulating an angio-
genic response in the drill channels, therefore restoring or
improving vascular flow to prevent further ischaemicFigure 1 (A) Dual X-Ray absorptiometry, (B) magnetic resonance
with bilateral osteonecrosis of the femoral head (red arrows), and
right and left femoral heads, respectively. The volume, angle, an
resonance imaging and (E) computed tomography for guiding furthepisodes and progressive bone infarction [36]. However,
clinical problems still exist, including incomplete recon-
structive repair and weakening of the trabecular bone
within and adjacent to the necrotic region [37]. Recently,
Mont et al [38] described a multiple drill-hole technique
using a 3.2-mm pin, and reported an 80% success rate for
treatment of early stage ONFH that did not need further
surgery within at least 7 years.
Core decompression combined with bone grafting pro-
duce an improved effect for ONFH through enhancing bone
formation and reducing the risk of proximal femoral frac-
ture, and this treatment has been recommended as a
routine treatment for precollapse ONFH [39,40]. Allo- or
auto-bone graft (cortical strut grafts taken from the ilium,
fibula, or tibia; cancellous bone graft taken from the
greater trochanter and proximal femur) that fill the drill
channels not only offer structural support, but also provide
scaffolding for repair (Figure 2) [21,41]. However, these
procedures will still have potential risk of viral or bacterial
infections and immune response [42,43]. Ceramic and bio-
glass implants are also widely used in bone surgical repairs
and are able to form bone apatite-like material or car-
bonate hydroxyapatite on their surfaces, enhancing their
osseointegration, however, brittleness and slow degrada-
tion rates of these materials are disadvantages for their use
[44e46]. Metals as implant materials (such as stainless
steel, titanium and its alloys, and tantalum) have advan-
tages due to their excellent mechanical properties and
porous surfaces that serve as delivery systems for special
growth factors [44,47]. However, the lack of tissue adher-
ence and the lower rate of degradation result either in a
second surgery to remove the implant or in permanentimaging, and (C) computed tomography of a 41-year-old man
showing the Ficat and Arlet Stage II and Stage III lesions in the
d arc of osteonecrotic lesions are detected on (D) magnetic
er treatment.
Table 1 Classification systems of osteonecrosis of the femoral head.
Ficat and Arlet [10,11]
(Radiography)
Steinberg [12,13]
(Radiography; MRI; CT)
ARCO [14,15]
(Radiography; MRI; CT; scintigraphy)
JOA [18,19]
(Radiography; MRI; CT; scintigraphy)
Stage Description Stage Description Stage Description Stage Description
I Normal
(Patients are asymptomatic)
0 Normal physical examination
(Patients are asymptomatic)
0 None I Demarcation line
Subdivided by relationship to
weight-bearing area:
A: medial
B: central
C: lateral
II Diffuse sclerotic and cystic
lesions
The integrity structure of hip
(Patients have mild intermittent
pain in the groin that radiates
down the inner aspect of the
thigh and a normal gait)
I Normal radiography
Abnormal CT and MRI
(Patients are asymptomatic)
I Normal radiography and CT and
at least one of the other physical
examination methods is positive
Area of femoral head involvement:
A: minimal < 15%
B: moderate 15e30%
C: extensive > 30%
Length of crescent:
A: < 15%
B: 15e30%
C: > 30%
Surface collapse and dome depression:
A: < 15% of and < 2 mm
B: 15e30% and 2 to 4 mm
C: > 30% and > 4 mm
(Patients are asymptomatic)
II Early flattening without
demarcation line around
necrosis area
III Subchondral fracture
Crescent sign
(Patients have increased pain
and crepitus during changes in
position particularly when
arising from sitting)
II Diffuse sclerotic
Cystic lesions
Area of cystic lesions involvement:
A: Mild < 15%
B: Moderate 15e30%
C: Severe: > 30%
(Patients are asymptomatic)
II Sclerosis
Osteolysis
Focal porosis
(Patients have mild intermittent pain
in the groin that radiates down the
inner aspect of the thigh and a
normal gait)
III Cystic lesions
Subdivided by site in the
femoral head:
A: medial
B: central
C: lateral
IV Femoral head collapse
Joint destruction
Osteoarthritis
Acetabular degeneration
(Patients have pain with
activity)
III Subchondral fracture
Crescent sign
Area of articular surface involvement:
A: Mild < 15%
B: Moderate 15e30%
C: Severe: > 30%
(Patients have mild intermittent pain
in the groin that radiates down the
inner aspect of the thigh and a
normal gait)
III Crescent sign
Flattening of femoral head
(Patients have increased pain and
crepitus during changes in position
particularly when arising from
sitting)
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Treatment of osteonecrosis of the femoral head 61implantation in the body with the related risks of toxicity
due to accumulation of metal ions caused by corrosion
[48,49]. In addition, patients who continue steroid therapy
after decompression have a worse prognosis [50]. Recently,
pure magnesium and its alloy coated with microarc oxida-
tion and electrophoresis deposition have been shown to
reduce the degradation rate of magnesium and have great
potential as promising biodegradable implantation mate-
rials and internal fixators [51]. Although core decompres-
sion seems to be more effective than purely symptomatic
treatment, it must be performed in the precollapse stage,
because it will not restore femoral head sphericity or
remove the collapsed segments from the weight-bearing
area [34,36].
Osteotomy
Osteotomies are used to rotate the necrotic or collapsing
segment of the hip out of the weight-bearing zone or tomove
the segments of necrotic bone away and replace them with a
healthy viable bone [6,22,52]. This procedure could change
the biomechanical effect, and reduce venous hypertension
and intramedullary pressure [52]. Osteotomies are usually
recommended to younger patients (aged < 45 years) [53].
These surgical procedures include transtrochanteric rota-
tional osteotomy and intertrochanteric angular osteotomy
[54,55]. However, the prognosis of these two procedures is
difficult to compare because there are ethnic differences [7].
Transtrochanteric rotational osteotomy only applied to Asian
countries because the posterior capsule of the hip in Asians
may be more lax and may allow for better rotation of the
anterior portion of the femoral neck. On the contrary, the
intertrochanteric angular osteotomy has been more success-
ful in Caucasians due to above anatomic difference [7,56].
However, poor fixation with screws may cause increased
various deformity, delayed union, and even secondary
collapse of the femoral head [57]. Osteotomy is used rarely,
because this procedure is only suitable for patients with the
following criteria: (1) aged < 45 years; (2) not being treated
with long-term steroids; (3) with minimal osteoarthritic
changes; (4) a small necrotic angle; and (5) without acetab-
ular involvement [53,58].
Arthroplasty
Limited femoral resurfacing with cement fixation is usually
used in younger patients. In this procedure, the damaged
cartilage on the femoral side is removed, the viable
acetabular cartilage is retained, and bone stock is pre-
served [59]. However, this limited femoral resurfacing
surgery requires years of rigorous training and great skill,
because these procedures have high failure rates and are
closely related to femoral neck fracture [60,61]. Mont et al
[59] recommend that patients with the following criteria
are chosen for limited femoral resurfacing: (1) Ficat and
Arlet Stage III; (2) necrotic angle of > 200 or necrotic area
> 30%; (3) femoral head collapse of > 2 mm; and (4) the
acetabular cartilage has not been damaged.
In addition, full resurfacing arthroplasty has become an
increasingly popular choice for younger patients with end-
stage arthritis [62,63]. Parsons and Steele [22] considered
that all operations were performed in special patients with
the following criteria: (1) necrotic area < 35%; (2) femoral
head neck junction integrity remains preserved; and (3) the
Table 2 Treatment options and their advantages and disadvantages.
Treatment options Criteria Advantages isadvantages References
Untreated Asymptomatic ONF Spontaneous
repair in
exceptional cases
oor outcome
eveloping to
ymptomatic
[2e5]
Nonoperative
therapy
Restriction of
weight-bearing
The early stage of ONFH
(Ficat and Arlet Stage I)
Giving pain relief ery limited for
reventing disease
rogression
[20e22]
Drugs With known aetiological
pathway
As prevention
treatment
Supplement
treatment for
operation
ery limited
enefits
ot appropriate
or collapse
[23e26,30e32]
Physical therapy With known physiological
factors
[27e29]
Core
decompression
Drill a single
8e10 mm core
Ficat and Arlet Stage II
Patients have mild
intermittent pain
Precollapse ONFH
Giving pain relief
Reducing
intraosseous
pressure
Stimulating
angiogenesis and
osteogenesis
ower mechanical
trength
econdary trauma
[35e37]
Drill a single
3.2 mm core
A [38]
Bone grafting Allo-bone grafting
Auto-bone grafting
Giving pain relief
Offering structural
support
Stimulating
angiogenesis and
osteogenesis
nfections
mmune response
[21,41e43]
Ceramics
Bioglass
igher brittleness
f implants
low degradation
ates
econdary trauma
[44e46]
Metal implants
Stainless steel
Titanium
Tantalum
ower tissue
dherence
ower rate of
egradation
etal ions toxicity
econdary trauma
[44,47e49]
Osteotomy Transtrochanteric
rotational osteotomy
Ficat and Arlet Stage II and
III
Patients have increased
pain
Patients < 45 years old
No long steroids using
history
A small necrotic angle
Giving pain relief
Changing
biomechanical
effect in lesion
region
Reducing
intramedullary
pressure
thnic differences
oor fixation
elayed union
econdary
eformity
econdary
ollapse
[7,52e58]
Intertrochanteric
angular osteotomy
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Minimal osteoarthritic
changes
Without acetabular
involvement
Arthroplasty Limited femoral
resurfacing
Ficat and Arlet Stage III
Patients have increased
pain or crepitus during
changes in position
Necrotic angle of > 200
Necrotic area >30%
Femoral head collapse
>2 mm
Without acetabular
cartilage involvement
Retaining the
viable acetabular
cartilage
Retaining the bone
stock
Higher failure
rates
Femoral neck
fracture
Dislocation of
femoral head
Secondary trauma
[59e61,67]
Full resurfacing Ficat and Arlet Stage III and
IV;
Necrotic area <35%;
Femoral head neck junction
integrity remains preserved;
Bone stock providing a
stable foundation for other
components.
Best choice for
younger patients
with end stage
arthritis
Dislocation of
femoral head
Secondary trauma
Groin pain
Limited implants
lifespan
[22,62e67]
Total hip arthroplasty Ficat and Arlet Stage IV;
Femoral head quality is very
poor
Continuing defective on
bone mineral metabolism
With acetabular cartilage
involvement
The only choice
for degenerated
hip joint
Greater
mechanical failure
rate
Limited implants
lifespan
Dislocation of
femoral head
Secondary trauma
[6,22,59,63,67]
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Figure 2 (AeE) The same patient as described in Figure 1 treated using core decompression and allo-bone grafting. (F) The
condition on the first postoperative day was delineated by dual X-ray absorptiometry; allo-bone implants were seen in the tunnel
(red arrows).
64 H. Cao et al.remains of bone stock could provide a stable foundation for
femoral components. This procedure involves replacing a
limited portion of the femoral head by a thin cemented
polyethylene acetabular component or the renaissance of a
large head [64,65]. The use of these devices for necrotic
hips has led to some concerns regarding vascular insult to
the femoral head and lower osteointegration rate of fixa-
tion components [66], and the design of devices does not
address pathology progression at the acetabular surface in
the later-stage ONFH, along with many complications
including wear, loosening, and groin pain [67]. However,
research has found that if good results are seen at an early
stage, they would be maintained for a long time.
Once the hip joint has degenerated (the articulation was
compromised), total hip arthroplasty (THA) will be needed.
However, there is no consensus regarding the utilization of
total hip replacement in particular patients with sickle cell
disease, systemic lupus erythematosus, postrenal trans-
plant and ongoing steroid use or alcohol abuse [22]. Mont
et al [6,59] and Parsons and Steele [22] also recommend
that patients considered for total hip replacement should
meet the following criteria: (1) the femoral head quality is
very poor; (2) there may be continuing defective bone
mineral metabolism; and (3) hip is subjected to continuing
insults. However, there is a greater mechanical failure rate
in patients aged  50 years; wearing and loosening aremajor complications of THA [63,67]. Currently, the use of
contemporary cementing techniques or uncemented com-
ponents combined with improved bearing surfaces could
reduce wear and improve longevity of implants [22]. In
addition, coupled with the larger head combinations made
possible by hard-on-hard bearing surfaces, this should
reduce the loosing or dislocation risk [22]. Recently, metal-
on-metal and ceramic-on-ceramic bearing surfaces have
become more popular in clinical application. Correctly, the
potential advantages of resurfacing over THA are lower
dislocation rates, preservation of bone stock, and THA
conversion could be performed if necessary [63,67].
Potential therapies for ONFH and their
translational barriersdscaffold-based bone
tissue engineering combined with biofactors
Bone is in a constant state of osteoclasts resorbing the
matrix and osteoblasts forming the matrix during the adult
stage [68], and this well-balanced state is associated with
cellular and vascular events [69,70]. Various cellular me-
diators (growth factors, differentiation factors, cytokines,
and hormones) are sequestered in vascular and bone ma-
trix, and regulate bone metabolism, function, and regen-
eration [71,72]. Currently, evidence implies that the ONFH
Treatment of osteonecrosis of the femoral head 65deterioration is associated with the follow issues [73e77]:
(1) aberrant osteoclastic resorption activity; (2) continuous
higher vascular permeability; (3) sluggish reparative
angiogenesis and osteogenesis; (4) irreversible connective
tissue formation; (5) subsequent lower mechanical prop-
erties; (6) necrosis area diffusion; (7) severe joint fluid
seepage; and (8) necrosis spreading to joints. Vascular,
cellular, and matrix events are all involved in this advanced
pathological progression and affect each other [77]. To
date, biologics involving antiapoptosis, angiogenesis, and
osteogenesis pathways have been screened [78]. Selected
biologics (cellular mediators, osteogenic, and angioblastic
cells) were injected directly into necrotic regions or seeded
in scaffolds and then implanted in the bone defect site
where the lesion tissue was removed; these procedures
were performed in various preclinical models to test the
efficacy [79,80]. The scaffold combined with biologics
serves as a template to facilitate cell interactions and the
formation of bone-extracellular matrix that could be more
favourable to enhance reparative angiogenesis and osteo-
genesis compared with signal scaffold implant and cellular
mediator injection (Figure 3) [81e84].Figure 3 Potential therapy for osteonecrosis using biodegrada
dimensional; SEM Z scanning electron microscopy.The ideal material or composite used as the component
of the scaffold should be nonimmunogenic, nontoxic,
controllable, inexpensive, and readily available. A number
of scaffold components are currently available [44,84,85]
and include inorganic materials, organic materials, and
biologics. Through control of a variety of different but
inter-related parameters, there is the potential to develop
novel and increasingly advanced composites [44,85]. For
example, polymers have the advantage of biocompatibility,
however, their low mechanical strength and high rates of
degradation often affects their use, chemical modification,
or other materials participation to improve these polymers
implants physical properties and bioactivity. Furthermore,
composite scaffolds could also incorporate some biofactors
to make a potential bone graft substitute available
[44,86,87]. In 1998, the first implantation of a porous
ceramic seeded with in vitro-expanded autologous osteo-
genic cells was performed in a bone segmental defect of a
patient and it exhibited a good integration and repair
process at the interface with the host bone [88,89]. Since
then, a few other similar cases were treated using the same
approach [80]. In the last 15 years, bone marrowble three-dimensional scaffolds with biofactors. 3D Z three
66 H. Cao et al.mesenchymal stem cells, bone marrow cells, periosteal
cells, platelet-rich plasma, and/or recombinant human
bone morphogenetic proteins 2 and 7 (rhBMP-2 and rhBMP-
7) have been incorporated into degradable porous scaffolds
as implants for bone defect and necrotic cartilage repair in
orthopaedic patients [90e95]. However, the use of scaf-
folds combined with biofactors in clinical practice has
several major inconveniences [80]. The contribution of the
biofactors to the bone formation was difficult to evaluate
due to the lack, or inadequacy, of control group patients
[96e98]. The success rate is higher, but complications or
nonunions are common, especially in large shaft re-
constructions [80,99]. rhBMP-2 has been the most
commercially successful bone tissue engineering product,
being utilized in up to 25% of all spinal fusion procedures
[99]. However, there have been significant complications
with rhBMP use, including patient death, dysphagia, airway
compression in spine fusion, and heterotopic bone forma-
tion in the spinal canal [100,101]. In addition, clinical trials
of rhBMP-2 incorporation showed risks of cancer, causing
the Food and Drug Administration (FDA) to halt its clinical
study [102]. The clinical gold standard remains the vascu-
larized free-fibular graft. Although billions of dollars in
research funding has been input to explore novel available
scaffolds, translation of scaffold-based bone tissue engi-
neering therapies to clinical use is required in the future
[103]. Technical and business barriers are critical issues
resulting in failed translations and there is a need to
address this long-term development.
Dr Scott Hollister [102] provided the 4Fs overview of
scaffolds, which served as the fundamental framework for
bone tissue engineering, and should be considered in the
design of an effective scaffold. The 4Fs are Form, Func-
tion, Fixation, and Formation. Form refers to the ability
to conform the 3D shape and fill the bone defect site.
Function refers to the mechanical properties of the scaf-
fold and requires that scaffolds provide temporary me-
chanical load bearing within a bone defect. Fixation
refers to the ability of the scaffold to integrate and attach
to the existing neighbouring bone and soft tissue with
good biocompatibility. Formation indicates that scaffolds
have a good osteoconductivity, features which are related
to porosity, permeability, diffusivity, and delivering
osteoinductive factors, including cells, proteins, and
genes. Finding a scaffold that addresses all the 4Fs
quantitative requirements is an extremely challenging
task. There is a common trade-off between the 4Fs during
scaffold design, because a strategy priority to promote
formation needs special materials or participation of
biofactors, which requires a preferable manufacturing
technique that intrinsically limits scaffold physical prop-
erties related to form, function, and fixation [104]. In
general, a scaffold development undergoes two phases
[85]: (1) scaffold fabrication needs to entail its physical
properties (elasticity, permeability, diffusivity, and
degradation) meet functional and formation requirements
through regulating the distribution and participation of
various materials and micropore structure in three-
dimensional space [44,105e108]; and (2) innovative bio-
materials with controlled biofactor release, combined
with a structural device such as surface creating to cater
for individual clinical design [109e111].Karageorgiou and Kaplan [44] systematically analysed
potential porous 3D biomaterial scaffolds according to their
physical properties and biological functions and provided
guidance regarding design choices of available bone grafts.
However, many successful scaffolds in preclinical models
may be implausible in some clinical applications due to
technical barriers. Firstly, the sequential fabrication tech-
nology needed to address all the 4Fs is difficult to achieve
due to the limitation of engineering and materials science
domain development [112,113]. Secondly, the safety and
efficacy of key parameter allocation involving trade-off of
the 4Fs are difficult to validate before a wide application in
clinics, because the assessment of patient responses is a
more complex task for heterogeneity of genetic background
and dissimilarity of bone defect types and bone loss pat-
terns [114]. Finally, the controlled biologic release system
in a scaffold makes it difficult to match desirable delivery
dose and time scale; existing biologic carriers use a very
higher dose delivered over a relatively short timescale,
which has led to many side effects such as oedema, het-
erotopic bone and vascular formation, and increased can-
cer risk [101,115]. The above issues require more
investigation in preclinical and clinical trials.
In addition, the business barrier is another critical issue
that needs to be addressed in scaffold-based bone tissue
engineering translation. The business challenges to trans-
lation include regulatory approval, obtaining external
funding support, obtaining surgeon acceptance, and
obtaining approval for insurance reimbursement [102]. This
procedure is very long and uncontrollable, with a need to
invest a lot of time, energy, and money. The first step is to
establish a quality system covering the scaffold design and
manufacturing, as well as a biofactor attachment
[116,117]. This would further assure scaffold biosafety and
reduce the investment risk to extend the scaffold product
to a combination product. The second step in conducting a
scaffold from discovery to the clinic is to assure the ma-
terial components used in the scaffold have been approved
by the FDA or China FDA. In parallel, the preclinical studies
required in a Class II or Pre-Market Approval application,
and the preclinical trials performed, should match Inter-
national Standards Organization 10993 guidelines
[117,118]. The last but the most important part is clinical
trials. In general, the clinical trial consists of 4 difference
research phases (Phase I, II, III, IV), and a commercially
scaffold need to require approvals from phase I to phase IV.
Unfortunately, many scaffolds fail to pass Clinical Trial
Phase II approval and then the relevant study is halted by
the FDA [102]. The failed cases imply that the successful
translation of scaffold-based bone tissue engineering still
requires more innovation techniques and preferable
biofactors.Future perspectives
Despite the challenges in bone tissue engineering being
very frustrating, there remains tremendous optimism
concerning the potential to replace damaged and degen-
erated structures and tissue. The integration of multiple
disciplines, such as cell biology, molecular biology,
biomechanics science, immunology, structure engineering
Treatment of osteonecrosis of the femoral head 67science, computer science, three-dimensional printing
technology, and translational science, may accelerate
bone tissue engineering development and product trans-
lation. These advances might improve bone healing by
alternative approaches in surgery and facilitate the prog-
nosis of ONFH.Conflicts of interest
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